Pharmaceuticals, Biotechnology and Life Sciences
Novartis’s Biologics License Application (BLA) for Zolgensma, designed to tackle the genetic root cause of spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease, was accepted by the U.S. Food and Drug Administration (FDA).
Read more
Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the
Read more
Shield Therapeutics said Monday that US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)
Read more
Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.
Read more
Redx might have an inhibitor of porcupine enzyme with a potential to treat fibrosis in human patients, it said on
Read more
Oasmia Pharmaceutical has made a deal with Baxter BioPharma Solutions to manufacture Apealea in its site in Germany, so Oasmia can focus on other products in its own facilities.
Read more
Novartis’s Gilenya became the first and only oral disease-modifying treatment for young patients with relapsing-remitting forms of multiple sclerosis (RRMS),
Read more
Tiziana Life Sciences has started the first-in-human Phase 1 clinical trial in healthy volunteers for Foralumab , which will be given to
Read more
ObsEva SA has started testing in third phase its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology (ART), or in-vitro fertilization (IVF).
Read more
Novartis’s eye care division Alcon, on Tuesday has its first Capital Markets Day for investors and analysts as a tax-neutral,
Read more